322 related articles for article (PubMed ID: 20813820)
1. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
[TBL] [Abstract][Full Text] [Related]
2. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.
Vinogradova Y; Coupland C; Hippisley-Cox J
BMJ; 2013 Jan; 346():f114. PubMed ID: 23325866
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).
Wright E; Schofield PT; Seed P; Molokhia M
PLoS One; 2012; 7(10):e47616. PubMed ID: 23112825
[TBL] [Abstract][Full Text] [Related]
4. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
[TBL] [Abstract][Full Text] [Related]
5. Exposure to oral bisphosphonates and risk of esophageal cancer.
Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
Oh YH; Yoon C; Park SM
World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
[TBL] [Abstract][Full Text] [Related]
7. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.
Busby J; Murchie P; Murray L; Iversen L; Lee AJ; Spence A; Watson MC; Cardwell CR
Int J Cancer; 2017 Apr; 140(8):1828-1835. PubMed ID: 28120338
[TBL] [Abstract][Full Text] [Related]
8. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.
Morden NE; Munson JC; Smith J; Mackenzie TA; Liu SK; Tosteson AN
Osteoporos Int; 2015 Feb; 26(2):663-72. PubMed ID: 25349053
[TBL] [Abstract][Full Text] [Related]
9. Exposure to oral bisphosphonates and risk of gastrointestinal cancer.
Choi D; Choi S; Chang J; Park SM
Osteoporos Int; 2020 Apr; 31(4):775-782. PubMed ID: 32034451
[TBL] [Abstract][Full Text] [Related]
10. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
[TBL] [Abstract][Full Text] [Related]
11. Oral bisphosphonates and oesophageal cancer.
Wysowski DK
BMJ; 2010 Sep; 341():c4506. PubMed ID: 20813821
[No Abstract] [Full Text] [Related]
12. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK-Clinical Practice Research Datalink.
Roddy E; Muller S; Paskins Z; Hider SL; Blagojevic-Bucknall M; Mallen CD
Medicine (Baltimore); 2017 Mar; 96(12):e6177. PubMed ID: 28328803
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study.
Spoendlin J; Meier C; Jick SS; Meier CR
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Andrici J; Tio M; Eslick GD
Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
[TBL] [Abstract][Full Text] [Related]
15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
16. Oral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers.
Vogtmann E; Corley DA; Almers LM; Cardwell CR; Murray LJ; Abnet CC
PLoS One; 2015; 10(10):e0140180. PubMed ID: 26445463
[TBL] [Abstract][Full Text] [Related]
17. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
[TBL] [Abstract][Full Text] [Related]
18. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA
BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527
[TBL] [Abstract][Full Text] [Related]
19. Exposure to oral bisphosphonates and risk of cancer.
Cardwell CR; Abnet CC; Veal P; Hughes CM; Cantwell MM; Murray LJ
Int J Cancer; 2012 Sep; 131(5):E717-25. PubMed ID: 22161552
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
Vestergaard P
Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
